Immunocore Holdings Ltd
$ 28.65
-3.08%
03 Jun - close price
- Market Cap 1,503,586,000 USD
- Current Price $ 28.65
- High / Low $ 29.79 / 27.97
- Stock P/E N/A
- Book Value 7.52
- EPS -0.56
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE -0.07 %
- 52 Week High 40.71
- 52 Week Low 27.55
About
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.
Analyst Target Price
$63.49
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-25 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-02-28 | 2023-11-07 | 2023-08-10 |
| Reported EPS | 0.25 | -0.6 | -0.0035 | -0.2 | 0.1 | -0.3714 | 0.17 | -0.23 | -0.49 | -32.22 | 0.05 | -0.37 |
| Estimated EPS | -0.26 | -0.197 | -0.24 | -0.21 | -0.4 | -0.1594 | -0.34 | -0.52 | -0.38 | -21.74 | -0.36 | -0.4 |
| Surprise | 0.51 | -0.403 | 0.2365 | 0.01 | 0.5 | -0.212 | 0.51 | 0.29 | -0.11 | -10.48 | 0.41 | 0.03 |
| Surprise Percentage | 196.1538% | -204.5685% | 98.5417% | 4.7619% | 125% | -132.9987% | 150% | 55.7692% | -28.9474% | -48.2061% | 113.8889% | 7.5% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.02 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IMCR
2026-06-02 09:09:15
Immunocore Holdings, a late-stage biotechnology company, announced updated data from its Phase 1/2 clinical trial of IMC-F106C (brentuximab vedotin) as a treatment for advanced cutaneous melanoma. The data indicated a median overall survival of 14.3 months, with a 6-month overall survival rate of 70%, suggesting potential as a monotherapy. Immunocore plans to initiate a Phase 3 randomized study in early 2025.
2026-06-02 04:09:15
This article provides an in-depth financial analysis of Immunocore Holdings PLC (IMCR), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company's primary revenue driver is product sales, accounting for 96.6% of total sales, alongside a significant gross margin of 99.59%. IMCR's market capitalization of $1.48B positions it as a leader in the pharmaceuticals sector.
2026-06-01 00:40:19
Immunocore announced updated Phase 1/2 data for brenetafusp in heavily pretreated, HLA-A*02:01-positive advanced melanoma patients, showing a median overall survival of 14.3 months and a 6-month survival rate of 87%. The data, presented at ASCO 2026, also indicated a 52% disease control rate and supported the selection of a 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial. Additionally, a second poster suggested IL7 may enhance ImmTAC T cell activity, which could further improve the efficacy of Immunocore’s therapies.
2026-05-31 14:10:22
Immunocore Holdings plc announced updated Phase 1/2 clinical trial data for brenetafusp in patients with advanced melanoma. The monotherapy showed an 87% 6-month overall survival rate and a 52% disease control rate in heavily pretreated patients, supporting the 160 mcg dose for the ongoing Phase 3 trial. Brenetafusp was generally well-tolerated both as a monotherapy and in combination with pembrolizumab, demonstrating consistent clinical benefits even in difficult-to-treat subgroups.
2026-05-29 13:09:15
Immunocore Holdings plc director John Irving Bell was granted 27,492 share options in a recent award. These options allow him to purchase ordinary shares at an exercise price of $28.52, with an expiration date of May 26, 2036. The options will vest at the earlier of May 27, 2027, or the day before the company's next annual general meeting, provided he remains in continuous service.
2026-05-29 02:08:43
Immunocore Holdings plc director Kristine Peterson was granted 27,492 stock options with an exercise price of $28.52 per share, expiring on May 26, 2036. The options will vest on the earlier of May 27, 2027, or the day before the company's next annual general meeting, provided her continuous service. This award is a compensation-related grant, not an open-market transaction.
